Effect of reinforcing kidney-essence, removing phlegm, and promoting mental therapy on treating Alzheimer's disease  by Liu, Ping et al.
TOPIC
JTCM |www. journaltcm. com August 15, 2013 |Volume 33 | Issue 4 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2013 August 15; 33(4): 449-454
info@journaltcm.com ISSN 0255-2922
© 2013 JTCM. All rights reserved.
CLINICAL STUDY
Effect of reinforcing kidney-essence, removing phlegm, and pro-
motingmental therapy on treating Alzheimer's disease
Ping Liu, Mingwang Kong, Songlin Liu, Gang Chen, PingWang
aa
Ping Liu, Mingwang Kong, Songlin Liu, Gang Chen, Ping
Wang, Key Laboratory of Senile Dementia, State Administra-
tion of Traditional Chinese Medicine of the People's Repub-
lic of China, Hubei University of Chinese Medicine, Wuhan
430065, China
Supported by the State Key Program of National Natural
Science of China (No. 81130064); Doctoral Fund of Ministry
of Education of China (No. 20094230110001) and National
Natural Science Foundation of China (No. 30901937)
Correspondence to: Prof. Ping Wang, Key Laboratory of
Senile Dementia, State Administration of Traditional Chi-
nese Medicine of the People's Republic of China, Hubei Uni-
versity of Chinese Medicine, Wuhan 430065, China.
lp_wh2008@126.com
Telephone: +86-18086662690
Accepted: February 22, 2013
Abstract
OBJECTIVE: To explore the mechanism of reinforc-
ing kidney-essence, removing phlegm, and promot-
ing mental therapy in treating Alzheimer's disease
(AD).
METHODS: Sixty patients with AD in Wuhan No.1
Hospital of Traditional Chinese Medicine for Geriat-
rics from May 2009 to April 2011 were randomly di-
vided into two groups, with 30 in each group. Pa-
tients in Bushenhuatanyizhi group (BHY group)
took BHY instant granules (6 g, twice per day). Pa-
tients in the control group took piracetam (0.8 g, 3
times per day). There were twelve weeks in a
course. Changes in the mini-mental state examina-
tion (MMSE) score and Activity of Daily Living Scale
(ADL) score were analyzed before and after treat-
ment.
RESULTS: MMSE scores in the two groups in-
creased and ADL scores decreased after treatment,
compared with those before treatment (both P<
0.05). The total effective rate was 86.67% in the BHY
group (10 very effective, 13 effective, 7 non-respon-
sive). The control group was 57.69% (5 very effec-
tive, 16 effective, 9 non-responsive) (P<0.05). Super-
oxide dismutase levels were increased, lipid perox-
ide and triglyceride levels decreased after treat-
ment in the BHY group as compared with the con-
trol group.
CONCLUSION: Reinforcing kidney-essence, remov-
ing phlegm, and promoting mental therapy can im-
prove cognitive function and daily life of AD pa-
tients. The mechanism of the therapy might be re-
lated to improving blood fat, scavenging free radi-
cals, and inhibiting lipid peroxides.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Alzheimer's disease (AD), characterized by progressive
deterioration in cognition, function, and behavior,
places a considerable burden on society. According to
recent surveys, it is the sixth leading cause of all deaths
and the fifth leading cause of death in persons aged ≥
65 years.1,2 An estimated 35.6 million people currently
sufferer from AD worldwide. Moreover, it is predicted
that AD will affect 1 in 85 persons globally by 2050.3,4
Currently, cholinesterase inhibitors and N-meth-
yl-D-aspartate receptor antagonists are first-line phar-
macotherapy in treating mild-to-moderate AD.5 How-
ever, they cannot prevent the condition of patients
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from deteriorating. As of 2012, more than 1000 clin-
ical trials have been or are being conducted to find
ways to treat AD. Therefore, finding an effective
method to treat AD still poses a significant clinical
challenge.6,7
Traditional Chinese Medicine (TCM) has a long histo-
ry of preventing and treating cognitive decline.8,9 Al-
though AD is a modern disease entity that has no di-
rect analogue in the ancient Chinese medicine litera-
ture, disorders of memory and cognitive deficit are re-
ferred to as dementia throughout the classical litera-
ture. For example, in Sheng Nong Ben Cao Jing, the ear-
liest pharmacopeia on materia medica in China, some
TCM ingredients such as Yuanzhi (Radix Palygalae),
Renshen (Radix Ginseng), Huanglian (Rhizoma Copti-
dis), and Longyanrou (Arillus Longan) were recorded to
ameliorate memory loss.10 Jing Yue Quan Shu contains
the earliest known description of herbal therapeutic
strategy for dementia.11 In Bian Zheng Lu, Shiduo
Chen proposed that "treating phlegm is treating de-
mentia". Shiduo Chen also suggested that tonifying
the spleen and stomach, resolving phlegm, and clearing
the orifices of the heart are important in the treatment
of dementia. A formula named Suxin Tang was devel-
oped for dementia. Suxin Tang is composed of Rensh-
en (Radix Ginseng), Fuling (Poria), Banxia (Rhizoma Pi-
nelliae), Chaihu (Radix Bupleuri Chinensis), Huanglian
(Rhizoma Coptidis), Wuzhuyu (Fructus Evodiae Rutae-
carpae), Zhizi (Fructus Gardeniae), Fuzi (Radix Aconi-
ti Lateralis Preparata), Danggui (Radix Angelicae Si-
nensis), Mudanpi (Cortex Moutan Radicis), and Suan-
zaoren (Semen Ziziphi Spinosae).12 Many Chinese
herbs including Shichangpu (Rhizoma Acori Tatari-
nowii), Yuanzhi (Radix Palygalae), Renshen (Radix
Ginseng), Cangzhu (Rhizoma Atractylodis Lanceae),
Gancao (Radix Glycyrrhizae), Banxia (Rhizoma Pinelli-
ae), Jianghuang (Rhizoma Curcumae Longae), Di-
huang (Radix Rehmanniae), Gouqizi (Fructus Lycii),
Roucongrong (Herba Cistanches Deserticolae), Shan-
yao (Rhizoma Dioscoreae Oppositae), and Fuling (Po-
ria) are used in senile dementia for memory and cog-
nitive function improvement.
In TCM, the AD clinical treatment take "reinforcing
deficiency and improving intelligence" and "supple-
ment deficiency without persisting pathogen" as the ba-
sic principle of treatment. Clinical practice showed
that replenishing kidney-essence, removing phlegm
and promoting mentality therapy is an effective to treat
AD. Experimental studies has demonstrated that this
therapy is effective in the treatment of mild cognitive
impairment, and early and moderate Alzheimer's dis-
ease.13-21 Bushenhuatanyizhi instant granules is the
main prescription for the therapy for AD.
Therefore, we conducted a clinical study to investigate
effect of reinforcing kidney-essence, resolving phlegm,
and promoting mental therapy in treating Alzheimer's
disease.
MATERIALS ANDMETHODS
Participants
Overall, 60 AD patients were selected from Wuhan
No.1 Hospital of TCM for Geriatrics from May 2009
to April 2011.
Patients were included if, referring to the diagnostic cri-
teria of the DSM-IV on AD and consulting the possi-
ble AD criteria of the NINCDS-ADRDA, they had
marrow deficiency, phlegm obstructing intelligence, Qi
stagnation, and blood stasis according to syndrome dif-
ferentiation of TCM.
Patients were excluded if they were ≤55 years old, had
a mini-mental state examination (MMSE) score <12,
had concomitant diabetes or diabetes history, had con-
comitant hypertension or hypertension history. The pa-
tients who met any one of the above items were exclud-
ed.
Patients were removed from the trial if they contracted
a serious disease that affected the trial in the observa-
tional period, experienced changes in their medication
plan, or whose treatment could not be judged due to
data loss.
Sixty AD patients consistent with enrollment standards
were divided into two groups using a randomized
block design. The Bushenhuatanyizhi instant granules
(BHY) group included of 30 patients (18 males and 12
females) with an average age of (74±5) years. The pi-
racetam group included of 30 patients (19 males and
11 females) with an average age of (75±6) years.
There was no significant difference in educational level
among patients (P>0.05). A written informed consent
form was obtained from subjects to analyze their diag-
nostic data retrospectively. The research protocol was
approved by the ethics committee of the Hospital of
TCM.
Therapeutic methods
Patients in the BHY group took BHY instant granules
(6 g, twice per day). BHY was composed of Heshouwu
(Radix Polygoni Multiflori), Zhujieshen (Rhizoma Pana-
cis Japonici), Shichangpu (Rhizoma Acori Tatarinowii),
Zhuru (Caulis Bambusae In Taeniam), Banxia (Rhizoma
Pinelliae), Fuling (Poria), and Yuanzhi (Radix Palyga-
lae). BHY was prepared by the Department of Pharma-
ceutical Preparation of Hubei Hospital of TCM (Wu-
han, China) (batch No. 2001006). Piracetam
(2-oxo-1-pyrrolidine-acetamide) is a cyclic derivative of
gamma-aminobutyric acid. Piracetam has been studied
in an extensive number of clinical experiments, and has
shown positive results in the treatment of dementia.22,23
Therefore, the control group took piracetam produced
by the Northeast General Pharmaceutical Factory
(Shen Yang, China, batch No. 200006066) (0.8 g, 3
times per day). There were twelve weeks in a course.
All patients had not taken a drug for the treatment of
AD from 2 weeks before the trial to the end of treat-
ment course.
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Curative effect assessment
Changes in MMSE or activity of daily living scales
(ADL) were observed for AD patients. Comparisons in
each group before and after treatment were conducted.
The MMSE24 covers various areas of cognitive domains
(e.g., orientation, memory, language, and visual con-
struction) and has become a widely used cognitive
screening tool in clinical research due to its brevity and
straightforward administration. The ADL is frequently
used in clinical trials for AD and assesses patient func-
tional ability.25
The MMSE scale is as follows. Very effective: the in-
crease of MMSE score was ≥4 after treatment. Effec-
tive: The increase of MMSE score was ≥2, and <4 after
treatment. Non-responsive: The increase of MMSE
score was <2 after treatment.
The ADL scale is as follows. Very effective: the de-
crease of ADL score was ≥6 after treatment. Effect: the
decrease of ADL score was ≥3, and smaller than 6 after
treatment. Invalidation: the increase of ADL score
was <3.
Measurement of SOD, LPO and TG in serum
Superoxide dismutase (SOD), lipid peroxide (LPO)
and triglyceride (TG) in serum were determined by col-
orimetric analysis using a spectrophotometer with the
associated detection kits (Nanjing Jiancheng Bioengi-
neering Institute, Nanjing, China). SOD, LPO and
LG levels are expressed as U/mL, mol/L and mol/L, re-
spectively.
Statistical analysis
SPSS 10.0 software (SPSS Inc., Chicago, IL, USA) was
used to do statistical analysis. T-test was used to do the
index comparison, before and after treatment, and the
level of significance was P<0.05.
RESULTS
MMSE scores before and after treatment
MMSE scores in the two groups increased after treat-
ment and were significantly different after treatment
(P<0.05). However, scores in the two groups were
not significantly different after treatment (P>0.05)
(Table 1).
ADL scores before and after treatment
ADL scores in the two groups decreased after treatment
and had a significant difference after treatment (P<
0.05). However, scores in the two groups were not signif-
icantly different after treatment (P>0.05) (Table 2).
Clinical effect after treatment
The total effective rate was 86.67% in the BHY group
(10 very effective, 13 effective, 7 non-responsive),
while the piracetam group was 57.69% (5 very effec-
tive, 16 effective, 9 non-responsive) (Table 3).
SOD activities after treatment
The activity of superoxide dismutase (SOD) in the
BHY group increased after treatment and had a signifi-
cant difference from before to after treatment (P<
0.05). However, the content of SOD was not signifi-
cantly different between the piracetam and BHY
groups after treatment (P>0.05) (Table 4).
LPO content after treatment
The results showed that the content of lipid peroxides
(LPO) in the BHY group decreased after treatment
and was significantly different after treatment (P<
0.05). However, LPO content was not significantly dif-
ferent between the piracetam and BHY groups after
treatment (P>0.05) (Table 5).
Group
Control
BHY
n
30
30
Before treatment
15.2±2.5
14.2±1.8
After treatment
18.7±2.1a
20.7±1.6a
Difference
3.4±1.3
6.1±1.1
Table 1 Comparison of MMSE scores before and after treatment ( xˉ ±s)
Notes: patients in the control group took piracetam; patients in the BHY group took Bushenhuatanyizhi instant granules. MMSE:
mini-mental state examination; BHY: Bushenhuatanyizhi. Compared with the same group before treatment, aP<0.05.
Group
Control
BHY
n
30
30
Before treatment
59.7±6.5
58.2±7.3
After treatment
54.3±6.5a
50.4±5.9a
Difference
−5.4±1.3
−7.9±1.3
Table 2 Comparison of ADL in two groups after treatment ( xˉ ±s)
Notes: patients in the control group took piracetam; patients in the BHY group took Bushenhuatanyizhi instant granules. ADL: activity of
daily living; BHY: Bushenhuatanyizhi. Compared with the same group before treatment, aP<0.05.
Group
Control
BHY
n
30
30
Very effective
5
10a
Effective
16
13
Non-responsive
9
7
Total effective rate (%)
57.69
86.67a
Table 3 Comparison of clinical effect in two groups after treatment
Notes: patients in the control group took piracetam; patients in the BHY group took Bushenhuatanyizhi instant granules. BHY:
Bushenhuatanyizhi. Compared with the same group before treatment, aP<0.05.
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TG content after treatment
Triglyceride (TG) levels in the BHY group decreased af-
ter treatment and differed significantly before and after
treatment (P<0.05). However, the TG levels were not
significantly different between the piracetam and BHY
groups after treatment (P>0.05) (Table 6).
Safety observation
Before and after treatment in the two groups, electro-
cardiogram examination, kidney function, and liver
function were normal. This indicated that BHY and pi-
racetam had no obvious toxic effects on the heart, liver,
or kidney.
DISCUSSION
Neuropsychological testing is very important for AD
diagnosis, evaluation, and prognosis. The MMSE and
ADL scales are used to measure cognitive function, liv-
ing activity, and the functions of learning, language, at-
tention, space, and movement. Changes in these test-
ing scores are closely correlated with AD severity.26-28
Our results suggest that Bushenhuatanyizhi instant
granules could significantly improve MMSE and ADL
scores, increase SOD activity, and decrease the levels of
LPO and TG after treatment. So we think, reinforcing
kidney-essence, resolving phlegm, and promoting men-
tal therapy can improve cognition and daily activities
of AD patients.
In TCM, energy from the kidney is called kidney es-
sence, which can produce marrows including cerebral,
spinal cord, and bone marrow. Huang Di Nei Jing said,
"The brain is the sea of marrow" and "kidney stores es-
sence to generate marrow".29 The cerebral marrow can
nourish the brain and maintain physiological function.
If the kidney essence is insufficient then the produc-
tion of cerebral marrow will be reduced, leading to vari-
ous symptoms, such as headache, dizziness, amnesia,
and diminished responsiveness.30-33 Meanwhile, TCM
holds that all prolonged diseases can be attributed to
phlegm. Phlegm-dampness and turbidity obstructing
the orifices are the pathogenesis of senile dementia.
Once a phlegm obstruction forms, the sea of marrow
becomes turbid, the spirit of brain loses nourishment,
the original spirit gets blocked, intelligence is damaged,
and sudden inspiration and memory become rotten.
Therefore, phlegm obstructions can lead to dementia.
We consider, weak kidney-essence and phlegm stasis is
the most basic pathogenesis of AD. Prescriptions for
AD should follow the principles in Chinese Medicine
to reinforce kidney-essence, remove phlegm, and pro-
mote mentality.34-36 Therefore, the treatment should
take cleaning and nourishing as principles. Clinical
treatment should involve "regulating the spirit and im-
proving intelligence" and "supplement deficiency with-
out persisting pathogen".37,38 Based on these theories,
we prescribed BHY which are composed of Heshouwu
(Radix Polygoni Multiflori), Zhujieshen (Rhizoma Pana-
cis Japonici), Shichangpu (Rhizoma Acori Tatarinowii),
Zhuru (Caulis Bambusae In Taeniam), Banxia (Rhizoma
Pinelliae), Fuling (Poria), Yuanzhi (Radix Palygalae),
Gancao (Radix liquiritiae). BHY reinforced kidney-es-
sence, removed phlegm, and promoted mental thera-
py.39,40
Recent studies showed that Shichangpu (Rhizoma Acori
Tatarinowii) tranquilized the mind, enhanced intelli-
gence, and opened orifices. The different fractions of
Table 6 Comparison of TG content in two groups after treatment (mol/L, xˉ ±s)
Group
Control
BHY
n
30
30
Before treatment
2.34±0.38
2.47±0.26
After treatment
2.18±0.36a
1.97±0.42a
Difference
0.16±0.02
0.50±0.16
Notes: patients in the control group took piracetam; patients in the BHY group took Bushenhuatanyizhi instant granules. TG: Triglycer-
ide; BHY: Bushenhuatanyizhi. Compared with the same group before treatment, aP<0.05.
Group
Control
BHY
n
30
30
Before treatment
5.34±1.38
5.47±1.26
After treatment
4.98±0.89a
4.37±1.02a
Difference
0.36±0.49
1.10±0.24
Notes: patients in the control group took piracetam; patients in the BHY group took Bushenhuatanyizhi instant granules. LPO: lipid per-
oxides; BHY: Bushenhuatanyizhi. Compared with the same group before treatment, aP<0.05.
Table 5 Comparison of LPO content in two groups after treatment ( mol/L, xˉ ±s)
Group
Control
BHY
n
30
30
Before treatment
53.8±5.8
54.7±8.5
After treatment
58.4±5.5a
64.3±6.8a
Difference
-5.4±1.3
-7.9±1.3
Table 4 Comparison of SOD activities in two groups after treatment (U/mL, xˉ ±s)
Notes: patients in the control group took piracetam; patients in the BHY group took Bushenhuatanyizhi instant granules. SOD: superox-
ide dismutase; BHY: Bushenhuatanyizhi. Compared with the same group before treatment, aP<0.05.
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Shichangpu extract such as the soluble and essential oil
fractions, could improve the learning and memory abil-
ities in AD mice induced by Aβ1-42. This effect might
be related to the decrease in nitric oxide synthase
(NOS) activity.41-43 Yuanzhi can significantly improve
learning and memory and promote long-term potentia-
tion (LTP) in the hippocampus in vivo. Its mechanism
may be related to promoting neurogenesis.44,45 In the
mouse model of dementia, refined Heshouwu, marked-
ly improved learning memory, lowered the contents of
lipofuscin and monoamine oxidase activity in the
brain, and enhanced the activities of superoxide dis-
mutase and catalase in the brain and NOS in the hip-
pocampus. Refined Heshouwu could protect the learn-
ing and memory capacity of mice with AD, which may
be related to the inhibition of apoptosis in the hippo-
campus.46,47 Yuanzhi (Radix Palygalae) dissolved
phlegm, opened orifices, and improved learning and
memory. Moreover, Yuanzhi (Radix Palygalae) extracts
can promote neuronal proliferation in the normal
brain and improve memory impaired by scopolamine
by inhibiting acetylcholinesterase (AChE) activity.48
There is suggestive evidence that Fuling (Poria) could
enhance hippocampal LTP and improve scopolamine
induced spatial memory impairment in rats. Fuling (Po-
ria)'s cognitive action has been ascribed to AChE inhi-
bition and bidirectional regulation of cytosolic free cal-
cium.49
In conclusion, reinforcing kidney-essence, resolving
phlegm, and promoting mental therapy is effective in
alleviating symptoms of dementia, improving cogni-
tion dysfunction, and daily function. After a 12-week
treatment, cognition and quality of daily life of the pa-
tients were improved obviously. There were no obvious
changes in experimental detections in the patients or
adverse events. Therefore, reinforcing kidney-essence,
resolving phlegm, and promoting mental therapy is
safe and tolerable.
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